サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566752

人工臓器と医療用バイオニクスの市場：タイプ別、技術別：世界の機会分析と産業予測、2024～2033年

Artificial Vital Organs and Medical Bionics Market By Type (Artificial Organs, Medical Bionics) , By Technology (Mechanical, Electronic) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
人工臓器と医療用バイオニクスの市場：タイプ別、技術別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

人工臓器と医療用バイオニクス市場は、2023年には474億米ドルと評価され、2024～2033年のCAGRは7.6%で、2033年には990億米ドルに達すると予測されています。

人工臓器は、臓器が損傷したり、機能不全に陥ったり、機能が損なわれた場合に、自然に発生する臓器の機能を代替・模倣する医療機器です。これらの機器は、失われた機能を回復させ、人間の能力を強化し、全体的な生活の質を向上させることを目的としています。一方、バイオニック・インプラントは、特定の機能を強化または回復させるために体内に埋め込んだり、身体に取り付けたりする電子的または機械的な装置です。バイオニックの原理に基づいて人間の臓器を製造するバイオ人工臓器製造技術の開拓は、人工生体臓器と医療用バイオニクス市場における重要なマイルストーンとして機能します。

世界の人工臓器と医療用バイオニクス市場の成長を牽引しているのは、薬剤療法、介入療法、外科療法の進歩にもかかわらず、臓器不全の症例が憂慮すべきほど増加していることです。深刻な臓器機能不全は、怪我や病気によるものだけでなく、視力や聴力の低下といった生命を脅かさない障害によるものもあり、これが生活の質を低下させるため、人工生命臓器の需要を増大させています。さらに、移植用のドナー臓器の不足が世界市場の主要な推進力となっています。臓器移植ネットワークの2024年3月の統計によると、米国保健福祉省との契約に基づいて運営されている臓器移植ネットワーク（UNOS）は、約10万3,223人の男性、女性、幼児を全米の移植待機者リストに入れています。同供給源によれば、毎日17人が臓器移植を待ちながら亡くなっています。さらに、高齢者人口の急増が世界市場の主要な原動力となっています。これは、高齢者が慢性疾患や機能障害による臓器不全に罹患しやすく、日々の家事をこなす能力が制限されるため、人工臓器ソリューションの需要が高まっていることに起因しています。世界保健機関（WHO）によると、60歳以上の高齢者数は2019年に10億人でした。この数は、2030年までに14億人、2050年までに21億人に増加すると推定されており、市場成長に大きく寄与する可能性が高いです。このように、これらすべての要因が臓器移植実施件数の増加に大きく寄与しています。Organ Procurement and Transplantation Networkの統計によると、2023年には46,000件以上の臓器移植が行われました。さらに、人工臓器移植に対する認識と受容の高まりが、市場の成長を促進しています。外傷を引き起こす事故事例の増加や、切断につながる糖尿病や末梢血管疾患の憂慮すべき有病率の上昇が、医療用バイオニクスの需要を促進しています。2020年にScienceDirect（科学、技術、医療研究の世界の主要情報源）に掲載された調査によると、米国では毎年約3万～4万件の民間人による負傷に関連した切断手術が行われています。切断者の需要増加に対応するため、メーカーはセンサーやアクチュエーターを搭載し、実際の手足の自然な動きや機能を模倣して運動性を大幅に向上させる先進的な義肢の開発に注力しています。しかし、人工臓器移植や医療用バイオニクスに伴う高コスト、免疫拒絶反応のリスク、倫理的対立が世界市場の主要な阻害要因となっています。逆に、人工臓器の技術的進歩は、予測期間中の市場拡大に有益な機会を提供すると期待されています。例えば、メーカーは人工臓器の機能性、モニタリング能力、全体的な有効性を高めることに注力しており、そのため人工臓器にバイオエレクトロニクスやデジタルヘルス技術を統合しており、これは今後数年間で臓器移植業界に革命をもたらすと予想されます。

人工臓器と医療用バイオニクス市場は、タイプ、技術、エンドユーザー、地域に区分されます。タイプに基づき、市場は人工臓器と医療用バイオニクスに分類されます。人工臓器はさらに、人工心臓、人工腎臓、人工肺、その他に区分されます。医療用バイオニクスは、さらに整形外科用バイオニクスとその他に区分されます。技術ベースでは、市場は機械式と電子式に二分されます。エンドユーザー別では、病院、外来手術センター、その他に分類されます。地域別では、市場は北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、人工臓器セグメントが2033年までに市場を独占すると予測されます。

技術別では、機械セグメントが予測期間中に最も高い成長を示すと予測されています。

エンドユーザー別では、病院セグメントが今後数年間で高い注目を集めると予測されています。

地域別では、北米が2023年の主要収益源であり、予測期間中も市場を独占する可能性が高いです。

本レポートで可能なカスタマイズ（追加費用とスケジュールがあります。）

  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 人工臓器と医療用バイオニクス市場：タイプ別

  • 市場概要
  • 人工臓器
    • 人工心臓
    • 人工腎臓
    • 人工肺
    • その他
  • 医療用バイオニクス
    • 整形外科用バイオニクス
    • その他

第5章 人工臓器と医療用バイオニクス市場：技術別

  • 市場概要
  • メカニカル
  • エレクトロニクス

第6章 人工臓器と医療用バイオニクス市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の人工臓器と医療用バイオニクス市場
    • カナダの人工臓器と医療用バイオニクス市場
    • メキシコの人工臓器と医療用バイオニクス市場
  • 欧州
    • 主要市場動向と機会
    • フランスの人工臓器と医療用バイオニクス市場
    • ドイツの人工臓器と医療用バイオニクスの市場
    • イタリアの人工臓器と医療用バイオニクス市場
    • スペインの人工臓器と医療用バイオニクス市場
    • 英国の人工臓器と医療用バイオニクスの市場
    • その他の欧州の人工臓器と医療用バイオニクスの市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国の人工臓器と医療用バイオニクス市場
    • 日本の人工臓器と医療用バイオニクス市場
    • インドの人工臓器と医療用バイオニクス市場
    • 韓国の人工臓器と医療用バイオニクス市場
    • オーストラリアの人工臓器と医療用バイオニクスの市場
    • その他のアジア太平洋の人工臓器と医療用バイオニクス市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの人工臓器と医療用バイオニクス市場
    • 南アフリカの人工臓器と医療用バイオニクスの市場
    • サウジアラビアの人工臓器と医療用バイオニクス市場
    • その他のラテンアメリカ・中東・アフリカの人工臓器と医療用バイオニクス市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • SynCardia Systems LLC
  • Abbott Laboratories, Inc.
  • Cochlear Limited
  • Boston Scientific Corporation
  • Johnson And Johnson
  • Edwards Lifesciences Corporation
  • Zimmer Biomet Holding Inc.
  • Berlin Heart GmbH
  • Jarvik Heart, Inc.
  • Medtronic Plc.
目次
Product Code: A00270

The artificial vital organs and medical bionics market was valued at $47.4 billion in 2023, and is projected to reach $99.0 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033.

Artificial vital organs are medical devices that replace and mimic the functions of naturally occurring organs in individuals whose organs are damaged, dysfunctional, or impaired. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life. Bionic implants, on the other hand, are electronic or mechanical devices that are implanted within or attached to the body to enhance or restore specific functions. The development of bioartificial organ manufacturing technologies to produce human organs based on bionic principles acts as a significant milestone in the artificial vital organs and medical bionics market.

The growth of the global artificial vital organs and medical bionics market driven by alarming increase in cases of organ failure, despite advancements in pharmacological, interventional, and surgical therapies. Serious organ dysfunction is not only caused due injuries or diseases but also due to nonlife-threatening disabilities such as loss of eyesight or hearing ability, which decreases the quality of life, thereby augmenting the demand for artificial vital organs. Moreover, shortage of donor organs for transplantation acts as a key driving force of the global market. According to the March 2024 statistics of the Organ Procurement and Transplantation Network-operated under contract with the U.S. Department of Health and Human Services by the United Network for Organ Sharing (UNOS)-approximately 103,223 number of men, women, and children are on the national transplant waiting list. As per the same source, 17 individuals die each day waiting for an organ transplant. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fac that aged individuals are highly susceptible to chronic diseases and organ failure due to functional impairment that limit the ability to carry out day-to-day chores, thus boosting the demand for artificial organ solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050, which is likely to significantly contribute toward the market growth. Thus, all these factors substantially contribute to increase in number of organ transplants carried out. The statistics derived from Organ Procurement and Transplantation Network suggest that more than 46,000 organ transplants were performed in 2023. In addition, rise in awareness and acceptance of artificial organ transplants is driving the growth of the market. Increase in cases of accidents causing traumatic injuries and alarming rise in prevalence of diabetes and peripheral vascular diseases that lead to amputations are driving the demand for medical bionics. According to a study published in 2020 in ScienceDirect-the world's leading source for scientific, technical, and medical research-approximately 30,000 to 40,000 civilian injury-related amputations are performed every year in the U.S. To meet the growing demand of amputees, manufacturers are focusing on the development of advanced prosthetic limbs equipped with sensors and actuators mimic the natural movement and functionality of real limbs, significantly improving mobility. However, high cost associated with artificial organ transplants and medical bionics, risk of immune rejection, and ethical conflicts act as the key deterrent factors of the global market. On the contrary, technological advancements in artificial vital organs are expected to offer remunerative opportunities for the expansion of the market during the forecast period. For instance, manufacturers are focusing on enhancing the functionality, monitoring capabilities, and overall effectiveness of artificial organs; thus, they are integrating bioelectronics and digital health technologies into artificial organs, which is expected to revolutionize the organ transplant industry in the coming years.

The artificial vital organs and medical bionics market is segmented into type, technology, end user, and region. Depending on type, the market is categorized into artificial organs and medical bionics. The artificial organs is further segmented into artificial heart, artificial kidney, artificial lungs, and others. The medical bionics is further segmented into orthopedic bionics and others. On the basis of technology, the market is bifurcated into mechanical and electronic. As per end user, it is classified into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the artificial organs segment is expected to dominate the market by 2033.

On the basis of technology, the mechanical segment is anticipated to exhibit highest growth during the forecast period.

Depending on end user, the hospital segment is projected to gain high prominence in the coming years.

Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial vital organs and medical bionics market include SynCardia Systems LLC, Abbott Laboratories, Inc., Cochlear Limited, Boston Scientific Corporation, Johnson & Johnson, Edwards Lifesciences Corporation, Zimmer Biomet Holding Inc., Berlin Heart GmbH, Jarvik Heart, Inc., and Medtronic Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast

Key Market Segments

By Type

  • Artificial Organs
    • Artificial Heart
    • Artificial Kidney
    • Artificial Lungs
    • Others
  • Medical Bionics
    • Orthopedic Bionics
    • Others

By Technology

  • Mechanical
  • Electronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • SynCardia Systems LLC
    • Abbott Laboratories, Inc.
    • Cochlear Limited
    • Boston Scientific Corporation
    • Johnson & Johnson
    • Edwards Lifesciences Corporation
    • Zimmer Biomet Holding Inc.
    • Berlin Heart GmbH
    • Jarvik Heart, Inc.
    • Medtronic Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Artificial Organs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Artificial Heart
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Artificial Kidney
      • 4.2.6.1. Market Size and Forecast
    • 4.2.7. Artificial Lungs
      • 4.2.7.1. Market Size and Forecast
    • 4.2.8. Others
      • 4.2.8.1. Market Size and Forecast
  • 4.3. Medical Bionics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Orthopedic Bionics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Others
      • 4.3.6.1. Market Size and Forecast

CHAPTER 5: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TECHNOLOGY

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Technology
  • 5.2. Mechanical
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Electronic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By Technology
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Vital Organs and Medical Bionics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By Technology
    • 6.2.6. Canada Artificial Vital Organs and Medical Bionics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By Technology
    • 6.2.7. Mexico Artificial Vital Organs and Medical Bionics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By Technology
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By Technology
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Artificial Vital Organs and Medical Bionics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By Technology
    • 6.3.6. Germany Artificial Vital Organs and Medical Bionics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By Technology
    • 6.3.7. Italy Artificial Vital Organs and Medical Bionics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By Technology
    • 6.3.8. Spain Artificial Vital Organs and Medical Bionics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By Technology
    • 6.3.9. UK Artificial Vital Organs and Medical Bionics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By Technology
    • 6.3.10. Rest of Europe Artificial Vital Organs and Medical Bionics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By Technology
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By Technology
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Artificial Vital Organs and Medical Bionics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By Technology
    • 6.4.6. Japan Artificial Vital Organs and Medical Bionics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By Technology
    • 6.4.7. India Artificial Vital Organs and Medical Bionics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By Technology
    • 6.4.8. South Korea Artificial Vital Organs and Medical Bionics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By Technology
    • 6.4.9. Australia Artificial Vital Organs and Medical Bionics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By Technology
    • 6.4.10. Rest of Asia-Pacific Artificial Vital Organs and Medical Bionics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By Technology
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By Technology
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Vital Organs and Medical Bionics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By Technology
    • 6.5.6. South Africa Artificial Vital Organs and Medical Bionics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By Technology
    • 6.5.7. Saudi Arabia Artificial Vital Organs and Medical Bionics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By Technology
    • 6.5.8. Rest of LAMEA Artificial Vital Organs and Medical Bionics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By Technology

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. SynCardia Systems LLC
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Abbott Laboratories, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Cochlear Limited
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Boston Scientific Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Johnson And Johnson
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Edwards Lifesciences Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Zimmer Biomet Holding Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Berlin Heart GmbH
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Jarvik Heart, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Medtronic Plc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments